AR052047A1 - Metodos de uso y composiciones comprendiendo moduladores de pde4 para el tratamiento prevencion y control de inflamacion de las vias respiratorias - Google Patents
Metodos de uso y composiciones comprendiendo moduladores de pde4 para el tratamiento prevencion y control de inflamacion de las vias respiratoriasInfo
- Publication number
- AR052047A1 AR052047A1 ARP050105222A ARP050105222A AR052047A1 AR 052047 A1 AR052047 A1 AR 052047A1 AR P050105222 A ARP050105222 A AR P050105222A AR P050105222 A ARP050105222 A AR P050105222A AR 052047 A1 AR052047 A1 AR 052047A1
- Authority
- AR
- Argentina
- Prior art keywords
- methods
- prevention
- compositions including
- inflammation treatment
- pde4 modulators
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 4
- 101100296720 Dictyostelium discoideum Pde4 gene Proteins 0.000 title abstract 2
- 206010061218 Inflammation Diseases 0.000 title abstract 2
- 101100082610 Plasmodium falciparum (isolate 3D7) PDEdelta gene Proteins 0.000 title abstract 2
- 230000004054 inflammatory process Effects 0.000 title abstract 2
- 238000011282 treatment Methods 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title 1
- 230000002265 prevention Effects 0.000 title 1
- 230000000241 respiratory effect Effects 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 239000013543 active substance Substances 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 239000002552 dosage form Substances 0.000 abstract 1
- 210000004072 lung Anatomy 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/4035—Isoindoles, e.g. phthalimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Indole Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US63498204P | 2004-12-13 | 2004-12-13 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR052047A1 true AR052047A1 (es) | 2007-02-28 |
Family
ID=36121316
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP050105222A AR052047A1 (es) | 2004-12-13 | 2005-12-13 | Metodos de uso y composiciones comprendiendo moduladores de pde4 para el tratamiento prevencion y control de inflamacion de las vias respiratorias |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20060148882A1 (https=) |
| EP (1) | EP1838294A1 (https=) |
| JP (1) | JP2008523102A (https=) |
| KR (1) | KR20070092276A (https=) |
| CN (1) | CN101111235A (https=) |
| AR (1) | AR052047A1 (https=) |
| AU (1) | AU2005316593A1 (https=) |
| BR (1) | BRPI0519030A2 (https=) |
| CA (1) | CA2590903A1 (https=) |
| IL (1) | IL183858A0 (https=) |
| MX (1) | MX2007006992A (https=) |
| WO (1) | WO2006065814A1 (https=) |
| ZA (1) | ZA200705540B (https=) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050100529A1 (en) * | 2003-11-06 | 2005-05-12 | Zeldis Jerome B. | Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of asbestos-related diseases and disorders |
| MXPA06012279A (es) * | 2004-04-23 | 2007-01-31 | Celgene Corp | Metodos de uso y composiciones que comprenden moduladores de pde4 para el tratamiento y manejo de la hipertension pulmonar. |
| BRPI0617673C1 (pt) * | 2005-10-19 | 2012-05-22 | Ranbaxy Lab Ltd | composições de inibidores de fosfodiesterase do tipo iv |
| EP2395995A1 (en) * | 2009-02-10 | 2011-12-21 | Celgene Corporation | Methods of using and compositions comprising pde4 modulators for treatment, prevention and management of tuberculosis |
| CN108059635B (zh) | 2009-05-14 | 2021-10-01 | 天津合美医药科技有限公司 | 噻吩衍生物 |
| MX341050B (es) * | 2010-04-07 | 2016-08-05 | Celgene Corp * | Metodos para tratar infeccion viral respiratoria. |
| JP6143675B2 (ja) | 2010-12-16 | 2017-06-07 | セルジーン コーポレイション | 難溶性薬物の制御放出経口剤形及びその使用 |
| JP2014505054A (ja) * | 2011-01-10 | 2014-02-27 | セルジーン コーポレイション | シクロプロパンカルボン酸｛２−［（１ｓ）−１−（３−エトキシ−４−メトキシ−フェニル）−２−メタンスルホニル−エチル］−３−オキソ−２，３−ジヒドロ−１ｈ−イソインドール−４−イル｝−アミドの経口剤形 |
| EP2663549B1 (en) * | 2011-01-10 | 2018-03-14 | Celgene Corporation | Phenethylsulfone isoindoline derivatives as inhibitors of pde 4 and/or cytokines |
| ES2711100T3 (es) | 2011-03-07 | 2019-04-30 | Celgene Corp | Métodos para tratar enfermedades usando compuestos isoindolina |
| JP6022548B2 (ja) | 2011-04-28 | 2016-11-09 | セルジーン コーポレイション | Ｐｄｅ４阻害剤を自己免疫疾患及び炎症性疾患の治療及び管理に使用する方法及び組成物 |
| WO2014151180A1 (en) | 2013-03-14 | 2014-09-25 | Celgene Corporation | Treatment of psoriatic arthritis using apremilast |
| WO2015112568A1 (en) * | 2014-01-24 | 2015-07-30 | Celgene Corporation | Methods for the treatment of obesity using apremilast |
| US10092541B2 (en) | 2014-08-15 | 2018-10-09 | Celgene Corporation | Methods for the treatment of diseases ameliorated by PDE4 inhibition using dosage titration of apremilast |
| US10011611B2 (en) | 2015-08-14 | 2018-07-03 | Reaction Biology Corp. | Histone deacetylase inhibitors and methods for use thereof |
| AU2017317123B9 (en) * | 2016-08-22 | 2021-11-25 | Medshine Discovery Inc. | PDE4 inhibitor |
| DK3590924T3 (da) * | 2017-02-28 | 2022-01-03 | Kangpu Biopharmaceuticals Inc | Hidtil ukendt isoindolinderivat og farmaceutisk sammensætning og anvendelse deraf |
| JP2020510071A (ja) * | 2017-03-16 | 2020-04-02 | タケダ ゲゼルシャフト ミット ベシュレンクテル ハフツング | 特発性肺線維症の治療 |
| GB202306663D0 (en) | 2023-05-05 | 2023-06-21 | Union Therapeutics As | Combination therapy |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6020358A (en) * | 1998-10-30 | 2000-02-01 | Celgene Corporation | Substituted phenethylsulfones and method of reducing TNFα levels |
| US6667316B1 (en) * | 1999-11-12 | 2003-12-23 | Celgene Corporation | Pharmaceutically active isoindoline derivatives |
| US6699899B1 (en) * | 1999-12-21 | 2004-03-02 | Celgene Corporation | Substituted acylhydroxamic acids and method of reducing TNFα levels |
| US6962940B2 (en) * | 2002-03-20 | 2005-11-08 | Celgene Corporation | (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof |
| US7276529B2 (en) * | 2002-03-20 | 2007-10-02 | Celgene Corporation | Methods of the treatment or prevention of exercise-induced asthma using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione |
| TW200501945A (en) * | 2002-11-06 | 2005-01-16 | Celgene Corp | Methods and compositions using selective cytokine inhibitory drugs for treatment and management of cancers and other diseases |
| EP1581205A1 (en) * | 2002-11-18 | 2005-10-05 | Celgene Corporation | Methods of using and compositions comprising (+)-3-(3,4-dimethoxy-phenyl)-3-(1-oxo-1,3-dihydro-isoindol-2-yl)-propionamide |
| BR0317885A (pt) * | 2002-12-30 | 2005-12-06 | Celgene Corp | Composto, isÈmeros s e r enantiomericamente puros do mesmo, composição farmacêutica e métodos de inibir pde4 e mmp, de modular a produção de tnf-alfa, de tratar ou prevenir mds, de tratar doença mieloproliferativa, angiogênese indesejada, câncer, uma doença, inflamação dos pulmões, depressão, distúrbio pulmonar obstrutivo crÈnico, doença inflamatória do intestino, dermatite atópica, psorìase, doença de crohn, artrite reumatóide, asma, eslcerose múltipla e doença cardìaca em um mamìfero e de tratar, prevenir ou controlar a sìndrome de dor regional complexa |
| MXPA06012279A (es) * | 2004-04-23 | 2007-01-31 | Celgene Corp | Metodos de uso y composiciones que comprenden moduladores de pde4 para el tratamiento y manejo de la hipertension pulmonar. |
| BRPI0418801A (pt) * | 2004-05-05 | 2007-10-16 | Celgene Corp | métodos de tratamento, controle ou prevenção de um cáncer especìfico, e de uma doença associada com angiogênese indesejada, de redução ou prevenção de um efeito adverso, composição farmacêutica, e, kit |
| US7244759B2 (en) * | 2004-07-28 | 2007-07-17 | Celgene Corporation | Isoindoline compounds and methods of making and using the same |
-
2005
- 2005-12-12 KR KR1020077015958A patent/KR20070092276A/ko not_active Withdrawn
- 2005-12-12 ZA ZA200705540A patent/ZA200705540B/xx unknown
- 2005-12-12 CA CA002590903A patent/CA2590903A1/en not_active Abandoned
- 2005-12-12 CN CNA2005800476591A patent/CN101111235A/zh active Pending
- 2005-12-12 MX MX2007006992A patent/MX2007006992A/es unknown
- 2005-12-12 WO PCT/US2005/045071 patent/WO2006065814A1/en not_active Ceased
- 2005-12-12 JP JP2007545718A patent/JP2008523102A/ja not_active Abandoned
- 2005-12-12 AU AU2005316593A patent/AU2005316593A1/en not_active Abandoned
- 2005-12-12 EP EP05853888A patent/EP1838294A1/en not_active Withdrawn
- 2005-12-12 BR BRPI0519030-4A patent/BRPI0519030A2/pt not_active IP Right Cessation
- 2005-12-13 AR ARP050105222A patent/AR052047A1/es not_active Application Discontinuation
- 2005-12-13 US US11/299,702 patent/US20060148882A1/en not_active Abandoned
-
2007
- 2007-06-12 IL IL183858A patent/IL183858A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2590903A1 (en) | 2006-06-22 |
| AU2005316593A1 (en) | 2006-06-22 |
| US20060148882A1 (en) | 2006-07-06 |
| WO2006065814A1 (en) | 2006-06-22 |
| IL183858A0 (en) | 2007-10-31 |
| CN101111235A (zh) | 2008-01-23 |
| MX2007006992A (es) | 2007-08-03 |
| KR20070092276A (ko) | 2007-09-12 |
| EP1838294A1 (en) | 2007-10-03 |
| BRPI0519030A2 (pt) | 2008-12-23 |
| ZA200705540B (en) | 2009-01-28 |
| JP2008523102A (ja) | 2008-07-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR052047A1 (es) | Metodos de uso y composiciones comprendiendo moduladores de pde4 para el tratamiento prevencion y control de inflamacion de las vias respiratorias | |
| US20190216779A1 (en) | Use of neurokinin-1 antagonists to treat a variety of pruritic conditions | |
| EA200600820A1 (ru) | Способы лечения, модификации и устранения боли с использованием 1-оксо-2-(2,6-диоксопиперидин-3-ил)-4-метилизоиндолина | |
| WO2005046318A3 (en) | Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of asbestos-related diseases and disorders | |
| BRPI0509400A (pt) | métodos para tratar ou prevenir sono disfuncional, para controlar sono disfuncional e para melhorar o tempo para o começo do sono, a duração do sono ou a qualidade do sono ou realçar a capacidade para levantar sentindo-se renovado depois de um sono noturno, composição farmacêutica, e, kit adequado para o uso no tratamento, prevenção ou controle de sono disfuncional | |
| AR060836A1 (es) | Un disco trans-mucosa para administrar un agente activo, una composicion trans-mucosa y el metodo de administracion obtenido | |
| CR9261A (es) | Composiciones terapeuticas para la administracion intranasal de ketorolac | |
| NI201100154A (es) | Métodos de uso y composiciones que comprenden moduladores de pde4 para el tratamiento, prevención y manejo de la tuberculosis | |
| CO6220945A2 (es) | Uso de una composicion que comprende formoterol y dipropianato de beclometasona para la prevencion y/o tratamiento de una exacerbacion de asma | |
| WO2004037207A3 (en) | Methods of using and compositions comprising selective cytokine inhibitory drugs for treatment, modification and management of pain | |
| UY29085A1 (es) | Derivados de pirimidina 4-sulfonamido sustituidos, compuestos intermedios para su preparación, procedimientos de preparación, composiciones medicinales conteniéndolos y aplicaci0nes | |
| AR046036A1 (es) | Composiciones de risedronato y metodos para su uso | |
| CL2024003616A1 (es) | Composición farmacéutica oral y uso para la terapia de enfermedades pulmonares intersticiales fibrosantes progresivas. | |
| BRPI0415651A (pt) | métodos para tratar, prevenir, modificar e/ou administrar fibromialgia, e para reduzir ou evitar um efeito adverso associado com a administração de um segundo ingrediente ativo em um paciente sofrendo de fibromialgia, e, composição farmacêutica | |
| WO2004037199A3 (en) | Methods of using and compositions comprising immunomodulatory compounds for treatment, modification and management of pain | |
| WO2005046594A3 (en) | Methods of using and compositions comprising a jnk inhibitor for the treatment and management of asbestos-related diseases and disorders | |
| AR048318A1 (es) | Formulaciones de matriz orales que comprenden licarbazepina | |
| AR074246A1 (es) | Derivados de 1-amino-alquilciclohexano para el tratamiento de trastornos del sueno | |
| MX2010013484A (es) | Formulaciones en dosis unitaria de ketorolaco para administración intra-nasal. | |
| WO2004041181A3 (en) | Methods of using and compositions comprising selective cytokine inhibitory drugs for treatment and management of macular degeneration | |
| WO2005046592A3 (en) | Methods of using and compositions comprising pde4 modulators for the treatment and management of asbestos-related diseases and disorders | |
| WO2009062193A3 (en) | Methods for administering corticosteroid formulations | |
| AR022348A1 (es) | Una composicion farmaceutica para el tratamiento de los sintomas del tracto urinario inferior | |
| BRPI0418798A (pt) | métodos de tratamento ou prevenção, e de controle, de uma doença mieloproliferativa, de redução ou prevenção de um efeito adverso, de aumento da eficácia terapêutica de um tratamento de doença mieloproliferativa, composição farmacêutica, e, kit | |
| BRPI0418800A (pt) | métodos de tratamento ou prevenção, e de controle, de uma doença mieloproliferativa, de redução ou prevenção de um efeito adverso, de aumento da eficácia terapêutica de um tratamento de doença mieloproliferativa, composição farmacêutica, e, kit |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |